Clinical Trials Logo
  1. Home
  2. Alpha 1-Antitrypsin Deficiency
  3. NCT02547532

Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency — AATD  

Alpha-1 Antitrypsin Deficiency Clinical Trial

Official title:
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency

Clinical Trial Summary

In the context of the increasing evidence of the pathogenetic role of microbiome in COPD, our aim is to determine the total and specific bacterial and viral load in sputa from patients with COPD due to AATD and to correlate these findings with cellular, biochemical and immunological characteristics of sputa. These quantitative data obtained from sputum will be analyzed in the context of the clinical and physiological parameters of the patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02547532
Study type Observational
Source Fondazione Salvatore Maugeri
Contact
Status Completed
Phase
Start date September 2015
Completion date April 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00005292 - Alpha1-antitrypsin Deficiency Registry N/A
Withdrawn NCT02900183 - Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Phase 2
Terminated NCT02502201 - Environment Effect on Six-Minute Walk Test Performance N/A
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Active, not recruiting NCT04262284 - Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Recruiting NCT06186492 - A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) Phase 1
Completed NCT01054339 - Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT03815396 - Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Phase 1
Completed NCT03008915 - Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT01419158 - Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT00500123 - The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Completed NCT05727800 - A Phase 1, First-in-human Study of VX-668 Phase 1
Active, not recruiting NCT05643495 - A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype Phase 2
Completed NCT02810327 - Alpha-1 Carrier Genomics Study
Terminated NCT02363946 - A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) Phase 1
Completed NCT03804021 - Long-Term Follow-up Study of ADVM-043
Active, not recruiting NCT02014415 - Alpha-1 Antitrypsin Deficiency Adult Liver Study
Terminated NCT01241942 - Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability N/A
Recruiting NCT01851642 - Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs